Novo Nordisk A/S (NYSE:NVO) Shares Sold by Arjuna Capital

Arjuna Capital lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 47,267 shares of the company’s stock after selling 6,116 shares during the quarter. Novo Nordisk A/S accounts for approximately 1.5% of Arjuna Capital’s holdings, making the stock its 17th largest holding. Arjuna Capital’s holdings in Novo Nordisk A/S were worth $5,628,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in NVO. Price T Rowe Associates Inc. MD raised its stake in shares of Novo Nordisk A/S by 10.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after purchasing an additional 823,036 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Novo Nordisk A/S by 1.4% in the second quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock worth $607,242,000 after purchasing an additional 58,935 shares during the last quarter. GQG Partners LLC raised its stake in shares of Novo Nordisk A/S by 654.6% in the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after purchasing an additional 3,151,584 shares during the last quarter. Raymond James & Associates raised its stake in shares of Novo Nordisk A/S by 1.0% in the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after purchasing an additional 36,223 shares during the last quarter. Finally, 1832 Asset Management L.P. raised its stake in shares of Novo Nordisk A/S by 7.8% in the first quarter. 1832 Asset Management L.P. now owns 2,373,029 shares of the company’s stock worth $304,697,000 after purchasing an additional 172,003 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets reduced their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $0.13 during trading on Wednesday, reaching $107.19. The stock had a trading volume of 441,864 shares, compared to its average volume of 4,428,569. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business has a fifty day moving average price of $120.23 and a 200-day moving average price of $130.08. The stock has a market cap of $481.02 billion, a PE ratio of 34.64, a PEG ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.